MICHELLE VESS: Open Payments
NPI 1528192697 · LONGVIEW, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$541 in 41 payments from 7 companies in 2025. Trend: 2023 $397 · 2024 $516 · 2025 $541
Food & beverage: $541
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $250 |
| ABBVIE INC. | 15 | $138 |
| E.R. Squibb & Sons, L.L.C. | 3 | $53 |
| Neurocrine BioSciences, Inc. | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 1 | $33 |
| Janssen Pharmaceuticals, Inc | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
Products named: CAPLYTA, VRAYLAR, COBENFY, INGREZZA, FANAPT, INVEGA SUSTENNA, UZEDY.
Industry payments across TX — which companies pay providers there.
